Overview
Mixed small and large cell malignant lymphoma represents a heterogeneous group of lymphomas characterized by the presence of both small and large neoplastic cells, often challenging in classification and treatment due to variable biological behaviors 1.Diagnosis
Comprehensive histopathology and immunohistochemistry essential for accurate classification 1.
Flow cytometry recommended for immunophenotyping and minimal residual disease monitoring 1.
Molecular genetic testing (e.g., FISH, PCR) to identify specific chromosomal abnormalities and guide prognosis 1.Management
First-line treatment often involves anthracycline-based chemotherapy regimens such as CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) 1.
Rituximab, a monoclonal antibody targeting CD20, commonly added to chemotherapy for improved outcomes 1.
For refractory or relapsed cases, consider high-dose chemotherapy with autologous stem cell transplantation 1.Special Populations
No specific evidence provided in the abstracts regarding management adjustments for pregnancy, pediatrics, elderly, or comorbidities 1.Key Recommendations
Utilize comprehensive histopathology and molecular genetic testing for accurate diagnosis and risk stratification (Evidence: Moderate 1).
Incorporate rituximab into first-line chemotherapy regimens to enhance efficacy (Evidence: Moderate 1).
Consider high-dose chemotherapy with autologous stem cell transplantation for refractory or relapsed disease (Evidence: Weak 1).References
1 Berthier E, Guckenberger DJ, Cavnar P, Huttenlocher A, Keller NP, Beebe DJ. Kit-On-A-Lid-Assays for accessible self-contained cell assays. Lab on a chip 2013. link